Cytoplasmic accumulation and aggregation of TDP-43 upon proteasome inhibition in cultured neurons.
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
Amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) are characterized by intraneuronal deposition of the nuclear TAR DNA-binding protein 43 (TDP-43) caused by unknown mechanisms. Here, we studied TDP-43 in primary neurons under different stress conditions and found that only proteasome inhibition by MG-132 or lactacystin could induce significant cytoplasmic accumulation of TDP-43, a histopathological hallmark in disease. This cytoplasmic accumulation was accompanied by phosphorylation, ubiquitination and aggregation of TDP-43, recapitulating major features of disease. Proteasome inhibition produced similar effects in both hippocampal and cortical neurons, as well as in immortalized motor neurons. To determine the contribution of TDP-43 to cell death, we reduced TDP-43 expression using small interfering RNA (siRNA), and found that reduced levels of TDP-43 dose-dependently rendered neurons more vulnerable to MG-132. Taken together, our data suggests a role for the proteasome in subcellular localization of TDP-43, and possibly in disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“proteasome inhibition using MG-132 leads to the cytoplasmic aggregation of TAR DNA-binding protein 43 (TDP-43) in cultured hippocampal and cortical neurons and in immortalized motor neurons (van Eersel et al., 2011).”
From Proteasome dysfunction induces muscle growth defects and protein aggregation (2014) · cites this paper as van Eersel et al., 2011
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., Bruce, J., Schuck, T., Grossman, M., Clark, C. M., et al. (2006) · Science · doi:10.1126/science.1134108 · Cited by 6,576 · cited 8×
“Since neurons are the primary cell type affected in FTLD-U and ALS, we tested the effects of proteasome inhibition on endogenous TDP-43 in primary cortical and hippocampal neurons or immortalized motor neurons.”
BackgroundResultInfluentialAssociation of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498
Protein aggregation and neurodegenerative disease
Ross, C. A., & Poirier, M. A. (2004) · Nature Medicine · doi:10.1038/nm1066 · Cited by 3,454 · cited 1×
“Pathological protein aggregates are frequently surrounded by proteasomes and lysosomes, however, these fail to fully remove the deposits [44,45].”
BackgroundArai, T., Hasegawa, M., Akiyama, H., Ikeda, K., Nonaka, T., Mori, H., Mann, D., Tsuchiya, K., Yoshida, M., Hashizume, Y., et al. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.10.093 · Cited by 2,732 · cited 1×
“Similar ubiquitin-positive inclusions are also found in motor neurons and some other neurons in ALS, and can contain either aggregated TDP-43 [11,12] and/or FUS [13].”
BackgroundTDP-43 Mutations in Familial and Sporadic Amyotrophic Lateral Sclerosis
Sreedharan, J., Blair, I. P., Tripathi, V. B., Hu, X., Vance, C., Rogelj, B., Ackerley, S., Durnall, J. C., Williams, K. L., Buratti, E., et al. (2008) · Science · doi:10.1126/science.1154584 · Cited by 2,630 · cited 2×
“Cell culture, as well as yeast and animal models have provided insights into TDP-43 pathology [17,18,20,40,41,42].”
BackgroundBrooks, B. R. (1994) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(94)90191-0 · Cited by 2,140 · cited 1×
“ALS often leads to death within three years of diagnosis [1,2].”
BackgroundMutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17
Baker, M., Mackenzie, I. R., Pickering-Brown, S. M., Gass, J., Rademakers, R., Lindholm, C., Snowden, J., Adamson, J., Sadovnick, A. D., Rollinson, S., et al. (2006) · Nature · doi:10.1038/nature05016 · Cited by 2,058
Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models
Ittner, L. M., Ke, Y. D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., Wölfing, H., Chieng, B. C., Christie, M. J., Napier, I. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.06.036 · Cited by 1,821
Self-citationThe roles of intracellular protein-degradation pathways in neurodegeneration
Rubinsztein, D. C. (2006) · Nature · doi:10.1038/nature05291 · Cited by 1,625 · cited 2×
“Proteasome dysfunction has been implicated in several neurodegenerative disorders, including ALS [43,46].”
BackgroundTARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis
Kabashi, E., Valdmanis, P. N., Dion, P., Spiegelman, D., McConkey, B. J., Velde, C. V., Bouchard, J.-P., Lacomblez, L., Pochigaeva, K., Salachas, F., et al. (2008) · Nature Genetics · doi:10.1038/ng.132 · Cited by 1,544 · cited 4×
“Cell culture, as well as yeast and animal models have provided insights into TDP-43 pathology [17,18,20,40,41,42].”
BackgroundResultInfluential
Cited by
Items 101–131 of 131
TDP-43 oligomerization and RNA binding are codependent but their loss elicits distinct pathologiesPreprint
Pérez‐Berlanga, M., Wiersma, V. I., Zbinden, A., Vos, L. D., Wagner, U., Foglieni, C., Mallona, I., Betz, K. M., Cléry, A., Weber, J., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.23.493029 · Cited by 5
Mechanistic insights of molecular chaperone Hsp70: Pathogenesis of neurodegenerative diseases
Choudhary, A., Kumar, P., Jagtap, Y. A., Kinger, S., Jha, H. C., Gutti, R. K., Sharma, V., Prajapati, V. K., & Mishra, A. (2025) · Brain Network Disorders · doi:10.1016/j.bnd.2025.05.001 · Cited by 6
Schizandrin reduces cytoplasmic TDP-43 accumulation in hippocampal neuronal cells
Oh, J., & Lee, N. K. (2017) · Biotechnology and Bioprocess Engineering · doi:10.1007/s12257-016-0656-9 · Cited by 4
“normal cells; however, the proteins are accumulated in the cytoplasm when their degradation is restricted [25].”
BackgroundKochen, N. N., Murray, M., Vunnam, N., Liao, E. E., Chen, L., Braun, A. R., & Sachs, J. N. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.11.617905 · Cited by 4
Understanding In Vitro Pathways to Drug Discovery for TDP-43 Proteinopathies
Cheng, H. W. A., Callis, T. B., Montgomery, A. P., Danon, J. J., Jorgensen, W. T., Ke, Y. D., Ittner, L. M., Werry, E. L., & Kassiou, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314769 · Cited by 3
Self-citationChemical and Biological Mechanisms Relevant to the Rescue of MG-132-Treated Neurons by Cysteine
Ückert, A., Suciu, I., Land, A., Spreng, A., Welte, H., Herzog, D., Basler, M., & Leist, M. (2025) · Antioxidants · doi:10.3390/antiox14020128 · Cited by 3
From Evasion to Collapse: The Kinetic Cascade of TDP-43 and the Failure of Proteostasis
Jamerlan, A., & Hulme, J. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031136 · Cited by 3
“Additionally, proteasome inhibition has been shown to drive the cytoplasmic accumulation and aggregation of neuronal TDP-43, supporting the central role of the UPS in degrading soluble TDP-43 species [51].”
Protein aggregation and Arfaptin2: A novel therapeutic target against neurodegenerative diseases
Mohammedeid, A. M., Lukashchuk, V., & Ning, K. (2014) · European Journal of Molecular & Clinical Medicine · doi:10.1016/j.nhtm.2014.08.004 · Cited by 2
“Therefore, it seems that TDP-43 distribution is controlled, at least partly, by the proteasome system and that a first hit, such as TDP-43 mutation, increases the cell vulnerability and a second hit, such as proteasome dysfunction, induces neurodegeneration and vice versa [27].”
BackgroundMitochondrial involvement in neuronal cell death
Gray, J. J. (2014) · Digital Commons - DU (University of Denver)
The Role of clusterin in motor neuron disease and the molecular mechanism of its action
Whiten, D. R. (2016) · Research Online (University of Wollongong)
Cumbay, M. G., LaFontaine, M., & Arbor, S. (2018) · Springer eBooks · doi:10.1007/978-981-13-0944-1_20
Znaidi, R., Massiani-Beaudoin, O., Mailly, P., Monnet, H., The Brainbank Neuro-CEB Neuropathology Network, Joshi, R. L., & Fuchs, J. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.10.552479
El‐Mansy, M. F., Soares, P., dos Remedios, J. R. D., Nowar, R., Fox, S. G., Yu, A., Klein, W. L., Morimoto, R. I., & Silverman, R. B. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109190
Cellular modifiers of TDP-43 phase transition and cytoplasmic aggregation
Chin, N. Y., Zhang, Q., Zou, J., Cheng, K. C.-C., Zheng, W., & Ye, Y. (2026) · eLife · doi:10.7554/elife.110172.4 · Cited by 1
Ueda, T., Takeuchi, T., Fujikake, N., Suzuki, M., Minakawa, E. N., Ueyama, M., Fujino, Y., Kimura, N., Nagano, S., Yokoseki, A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26676047
ATH-1105 mitigates multiple pathologies in ALS models both alone and in combination with riluzole
Berthiaume, A., Kleist, K. N., Reda, S. M., Setti, S. E., Wu, W., Johnston, J. L., Taylor, R. W., Stein, L. R., & Church, K. J. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2025.1582765
TDP-43 pathology is linked to motor neuron loss and is independent of stress granules in vivoPreprint
Dubinski, A. F., Ferdi, A., Choughari, M., Spence, H., Adhikary, A., Fauchon, C., Touati, M., Gagné, M., Liu, M., Peyrard, S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.11.705439 · Cited by 1
Cellular modifiers of TDP-43 phase transition and cytoplasmic aggregationPreprint
Chin, N. Y., Zhang, Q., Zou, J., Cheng, K. C.-C., Zheng, W., & Ye, Y. (2026) · eLife · doi:10.7554/elife.110172 · Cited by 1
“This is consistent with previous studies in ALS models, which showed that proteasome stress accelerates TDP-43 aggregation and toxicity ( van Eersel et al., 2011 ).”
Nuclear export governs TDP-43 phase transitions and cytoplasmic aggregationPreprint
Chin, N. Y., Zhang, Q., Zou, J., Cheng, K. C.-C., Zheng, W., & Ye, Y. (2026) · eLife · doi:10.7554/elife.110172.1
TYK2 mediates neuroinflammation in Alzheimer’s disease brains with TDP-43 pathology
König, L. E., Rodriguez, S., Hug, C. B., Daneshvari, S., Chung, A., Appleman, M., Tsai, M., Bradshaw, G. A., Şahin, A., Song, Y., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-70243-3 · Cited by 9
“Next, to evaluate if this candidate biomarker can be seen in association with TDP-43 pathology, we modi fi ed our cell-based assay by treating differentiated ReN VM cells with 1 µ M MG-132, a proteasome inhibitor known to induce cytoplasmic aggregation of TDP-43 67,68 .”
Modeling C9ORF72 loss-of-function : a knockdown mouse model
Lopez-Herdoiza, M.-B. (2016) · theses.fr (ABES) · doi:10.70675/dfc77570z827az4993z840dz21dfc54360de
“Inhibition of the UPS increases TDP43 aggregation in cultured cells (Eersel et al., 2011), suggesting a direct link between the UPS and TDP43 aggregation.”
BackgroundGeneration and validation of a human iPSC-derived TDP-43 knockout model for ALS disease modelingPreprint
Gurumurthy, S., Bhargava, A., Huynh, N. P., Krzystek, T. J., Vieira, F. G., & Denton, K. R. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.29.720127 · Cited by 1
Molecular Dissection of TDP-43 as a Leading Cause of ALS/FTLD
漆谷, 真., Tamaki, Y., & URUSHITANI, M. (n.d.) · Institutional Repositories DataBase (IRDB)
Nuclear export modulates TDP-43 phase transition and cytoplasmic aggregationPreprint
Chin, N. Y., Zhang, Q., Zou, J., Cheng, K. C.-C., Zheng, W., & Ye, Y. (2026) · eLife · doi:10.7554/elife.110172.2 · Cited by 1
Cell Death in Neurodegenerative Diseases: Molecular Mechanisms and Therapeutic Targets
Li, T., Zhang, Q., Wu, Y., & Huang, R. (2026) · MedComm · doi:10.1002/mco2.70915 · Cited by 1
Cellular modifiers of TDP-43 phase transition and cytoplasmic aggregationPreprint
Chin, N. Y., Zhang, Q., Zou, J., Cheng, K. C.-C., Zheng, W., & Ye, Y. (2026) · eLife · doi:10.7554/elife.110172.3
Li, M., Li, R., Deng, Z., Zhang, L., Lv, S., Shi, J., Ma, H., Guan, W., Zhang, H., Li, J., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1918967
“Evidence indicates that loss of TDP-43 function associated with ALS can cause proteasome dysfunction, while inhibition of the proteasome in normal MNs can also induce cytoplasmic accumulation, aggregation, and insolubility of TDP-43, forming a vicious cycle (Van Eersel et al., 2011).”
Modulating TDP-43 Protein Aggregation Directly and Indirectly in C. Elegans
Elshaalia, E. (2026) · Digital Commons - DU (University of Denver) · doi:10.56902/etdcrp.2026.150
TDP-43 and ALS - what's wrong with my membranes?
Dahlhaus, R., Yalcin, I., Tischer, J., & Braun, R. J. (2026) · Neurobiology of Disease · doi:10.1016/j.nbd.2026.107630 · Cited by 1
Direct and Indirect Modulators of TDP-43 Aggregation in vitro
Caicedo, K. M. R. (2026) · Digital Commons - DU (University of Denver) · doi:10.56902/etdcrp.2026.187
Metadata
- Authors
- van Eersel, J., Ke, Y. D., Gladbach, A., Bi, M., Götz, J., Kril, J. J., & Ittner, L. M.
- Affiliations
- The University of Sydney (AU)
- Corresponding author
- Ittner, Lars M.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-07-29
- Volume
- 6
- Issue
- 7
- Pages
- e22850
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3146516
- OpenAlex
- W2088821814
- Cited by
- 130
- References
- 73
- Citations by year
- 2026: 15 · 2025: 9 · 2024: 12 · 2023: 9 · 2022: 6 · 2021: 7 · 2020: 8 · 2019: 8 · 2018: 8 · 2017: 5 · 2016: 10 · 2015: 9 · 2014: 9 · 2013: 11 · 2012: 4
- FWCI
- 4.87
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- National Science Council
- Medical Research Council
- Australian Research Council
- National Health and Medical Research Council
- Topics
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Keywords
- TDP-43, proteasome inhibition, cytoplasmic accumulation, protein aggregation, amyotrophic lateral sclerosis, frontotemporal lobar degeneration, neuronal stress, TDP-43 phosphorylation, ubiquitination, motor neurons, hippocampal neurons, cortical neurons, neurodegeneration
- MeSH terms
- Animals, Cell Nucleus, Cells, Cultured, Cytoplasm, DNA-Binding Proteins, Humans, Immunoenzyme Techniques, Leupeptins, Neurons, Phosphorylation, RNA, Messenger, Subcellular Fractions, Blotting, Western, Cysteine Proteinase Inhibitors, Cell Death, RNA, Small Interfering, Immunoprecipitation, Mice, Ubiquitination, Proteasome Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.